Acro Biomedical Co, LTD
Market Movers (8-K)
OTC.Pink
Acro Biomedical Co., Ltd. announced a change in its independent registered public accounting firm, dismissing KCCW Accountancy Corp. and engaging Weinberg & Company, while KCCW's prior reports included a going concern explanatory paragraph.
Worse than expected
OTC.Pink
ACRO Biomedical Co., Ltd. announced the resignation of Pao-Chi Chu as director, chairman, and chief executive officer, appointing Yu-Ting Su to succeed him, effective August 14, 2025.
OTC.Pink
Acro Biomedical Co., Ltd. has appointed KCCW Accountancy Corp. as its new independent registered public accounting firm, replacing Prager Metis CPAs, LLC.
Worse than expected
Quarterly Earnings (10-Q)
OTC.Pink
Acro Biomedical Co., Ltd. reported no revenue for the first quarter of 2026, with net losses widening to $43,774, primarily due to operating expenses and interest on related party loans.
Worse than expected
OTC.Pink
Acro Biomedical Co., Ltd. reported a significant increase in net loss for Q3 2025, with no revenue generated since late 2022, raising substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
OTC.Pink
Acro Biomedical Co., Ltd. reported continued net losses and no revenue for the second quarter and first half of 2025, raising substantial doubt about its ability to continue as a going concern.
Worse than expected
Delay expected
Capital raise
OTC.Pink
Acro Biomedical Co., Ltd. reported no revenue for Q1 2025, continued operating losses, and significant doubt about its ability to continue as a going concern, relying heavily on related party advances.
Worse than expected
Delay expected
Capital raise
OTC.Pink
Acro Biomedical Co., Ltd. reported no revenue for the third quarter and first nine months of 2024, with a growing accumulated deficit and significant going concern doubts.
Worse than expected
Delay expected
Capital raise
OTC.Pink
Acro Biomedical reports no revenue, continued losses, and significant going concern issues for Q2 2024, relying solely on related party advances.
Worse than expected
Capital raise
Annual Reports (10-K)
OTC.Pink
Acro Biomedical Co., Ltd. reports no revenue since late 2022, significant losses, and a going concern warning, alongside a recent CEO change and challenges in its cordyceps product market.
Delay expected
Worse than expected
Capital raise
OTC.Pink
Acro Biomedical Co., Ltd. filed its 2024 annual report, revealing no revenue, significant losses, and substantial doubt about its ability to continue as a going concern.
Worse than expected
Delay expected
Capital raise
OTC.Pink
Acro Biomedical Co., Ltd. filed its annual report for 2023, revealing no revenue, substantial net losses, and significant going concern doubts.
Worse than expected
Delay expected
Capital raise